Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development
Constellation Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Domainex Ltd
Epizyme Inc
Eternity Bioscience Inc
GlaxoSmithKline Plc
Hanmi Pharmaceuticals Co Ltd
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kainos Medicine Inc
OncoFusion Therapeutics Inc
Pfizer Inc
Transgene Biotek Ltd
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles
CPI-0209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-1205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPI-169 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EBI-2554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-343 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-97594 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONISEZH-22.5Rx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JQEZ-5 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-1943 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORS-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06821497 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-2554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH1 and EZH2 for Leukemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazemetostat hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBL-0404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valemetostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development Milestones
Featured News & Press Releases
Feb 14, 2020: Epizyme announces FDA acceptance of New Drug Application for filing with priority review for TAZVERIK (tazemetostat) for the treatment of Follicular Lymphoma
Jan 24, 2020: Epizyme’s Tazverik receives accelerated approval from FDA
Dec 18, 2019: Epizyme submits new drug application to the U.S. FDA for Tazemetostat for the treatment of patients with follicular lymphoma
Dec 18, 2019: Epizyme (EPZM) trading of stock halted; Oncology drug advisory committee to review Tazemetostat
Dec 18, 2019: Epizyme announces FDA Advisory Committee votes unimously in favor of Tazemetostat for the treatment of patients with epithelioid sarcoma
Dec 11, 2019: Daiichi Sankyo initiates Phase II study of valemetostat to treat ATL
Dec 09, 2019: Researchers create a potential therapy for deadly Breast Cancer that has few treatment options
Dec 07, 2019: Epizyme Presents Updated Phase 2 Data at the 2019 ASH Annual Meeting Supporting Planned Tazemetostat NDA Submission for Follicular Lymphoma
Dec 02, 2019: Epizyme announces FDA Advisory Committee Meeting to review Tazemetostat for the treatment of patients with epithelioid sarcoma
Nov 06, 2019: Daiichi Sankyo showcases data presentations on valemetostat at American Society of Hematology (ASH)
Oct 30, 2019: Epizyme announces positive pre-NDA meeting for Tazemetostat for Follicular Lymphoma
Sep 24, 2019: Constellation Pharmaceuticals advances CPI-0209 into Clinical Trials, expanding its EZH2 franchise
Jul 25, 2019: Epizyme announces FDA Filing Acceptance of New Drug Application and Priority Review for Tazemetostat for the Treatment of Epithelioid Sarcoma
Jun 24, 2019: Epizyme reports positive data from trial of FL therapy tazemetostat
Jun 12, 2019: Epizyme announces conference call to discuss phase 2 Tazemetostat follicular lymphoma data
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Constellation Pharmaceuticals Inc, H1 2020
Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Pipeline by Domainex Ltd, H1 2020
Pipeline by Epizyme Inc, H1 2020
Pipeline by Eternity Bioscience Inc, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
Pipeline by Ionis Pharmaceuticals Inc, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Pipeline by Kainos Medicine Inc, H1 2020
Pipeline by OncoFusion Therapeutics Inc, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Transgene Biotek Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020